Browse Tag

singapore

Scientists from the Experimental Drug Development Centre, A*STAR, performing real-time Reverse Transcription-Polymerase Chain Reaction (RT-PCR) to amplify the genetic material from ETC-159 clinical samples. From L-R: Ms Sylvia Gan, Senior Research Manager; Ms Nurul Rozaini, Research Associate (Photo credit: A*STAR)

July 30, 2020July 30, 2020

Made-in-Singapore Cancer Drug ETC-159 Advances Further in Clinical Trials

First dose of ETC-159 administered in Phase 1B of clinical trials, advancing the development of this drug to treat solid tumours Made-in-Singapore cancer drug, ETC-159, has achieved a new developmental milestone in achieving “First Patient First Visit[1]” in Phase 1B. The first dose of

Pharmaceutical Articles

Made-in-Singapore Cancer Drug ETC-159 Advances Further in Clinical Trials

July 30, 2020July 30, 2020

First dose of ETC-159 administered in Phase 1B of clinical trials, advancing the development of this drug to treat solid

Go toTop

<img src="http://www.pharmamirror.com/wp-content/uploads/2018/01/Pharma-Mirror.png" alt="Mobile Logo" width="330" height="77">

singapore

Made-in-Singapore Cancer Drug ETC-159 Advances Further in Clinical Trials

Made-in-Singapore Cancer Drug ETC-159 Advances Further in Clinical Trials